Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study

Prognostic Value of Baseline Medications Plus Neutrophil-to-Lymphocyte Ratio in the Effectiveness of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer: A Retrospective Study

BackgroundNivolumab and pembrolizumab are the standard treatments for patients with advanced non-small-cell lung cancer (NSCLC). While there are reports on several inflammatory indices and the prognosis of patients with cancer, no study has combined baseline medication with the neutrophil-to-lymphoc...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Toshiki Ogiwara, Hitoshi Kawazoe, Saeka Egami, Hironobu Hashimoto, Yoshimasa Saito, Naomi Sakiyama, Yuichiro Ohe, Masakazu Yamaguchi, Tetsuya Furukawa, Azusa Hara, Yui Hiraga, Aya Jibiki, Yuta Yokoyama, Sayo Suzuki, Tomonori Nakamura
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
nivolumab
pembrolizumab
baseline medications
neutrophil-to-lymphocyte ratio
prognostic score
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/b197c72349844806ab490770dcad20f3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/b197c72349844806ab490770dcad20f3

Ejemplares similares